دورية أكاديمية
Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies
| العنوان: | Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies |
|---|---|
| المؤلفون: | Xiaoqiang Liu, Juliana Park, Shengli Xia, Bin Liang, Shuangmin Yang, Yanxia Wang, Olga Syrkina, Nathalie Lavis, Shuzhen Liu, Chenyan Zhao, Jian Ding, Jieqiong Hu, Sandrine I. Samson, Iris A. de Bruijn, for the FSQ01 and FSQ02 Study Groups |
| المصدر: | Human Vaccines & Immunotherapeutics, Vol 18, Iss 6 (2022) |
| بيانات النشر: | Taylor & Francis Group, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Immunologic diseases. Allergy LCC:Therapeutics. Pharmacology |
| مصطلحات موضوعية: | china, elderly, immunogenicity, inactivated influenza vaccine, pediatric, quadrivalent, safety, Immunologic diseases. Allergy, RC581-607, Therapeutics. Pharmacology, RM1-950 |
| الوصف: | A quadrivalent, split-virion influenza vaccine (Shz QIV), containing two influenza A strains, and both B lineages strains, has been developed in China. We report the safety and immunogenicity of Shz QIV in two studies: a single-center, phase I, open-label, safety trial (n = 101) and a multicenter, phase III, observer-blind, randomized, safety and immunogenicity trial (n = 7,106) comparing Shz QIV with two trivalent influenza vaccines (Shz TIVs; one containing a B/Victoria-like strain and the other a B/Yamagata-like strain). Participants received one dose of Shz QIV (0.5 mL), except children aged 6 months to 8 years who received one or two doses (0.25 mL or 0.5 mL) depending on previous influenza vaccination. The Shz TIV groups received one or two (0.25 mL) doses depending on previous influenza vaccination (ages 6–35 months) or a single (0.5 mL) dose (ages ≥3 years). Immunogenicity was assessed at baseline and 28 days after the last dose, with safety assessed through to 6 months. The primary objective was to demonstrate the non-inferiority of antibody responses to Shz QIV (0.25 mL and 0.5 mL) versus Shz TIVs for each strain in ages 6–35 months and ≥3 years. Overall, Shz QIV was well tolerated, and showed similar safety to the Shz TIVs. Shz QIV (0.5 mL) induced non-inferior antibody responses to all antigens versus Shz TIV, with superiority demonstrated to the non-corresponding B strain in each TIV. Shz QIV (0.25 mL) non-inferiority in those aged 6–35 months was demonstrated for both A strains and the B/Yamagata-like strain, but not the B/Victoria-like strain. In summary, Shz QIV (0.5 mL) is immunogenic and has a good safety profile. WHO Universal Trial Numbers (UTNs) U1111-1174-4615 and U1111-1174-4698 ClinicalTrials.gov NCT04210349 and NCT03430089 |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2164-5515 2164-554X 21645515 |
| العلاقة: | https://doaj.org/toc/2164-5515Test; https://doaj.org/toc/2164-554XTest |
| DOI: | 10.1080/21645515.2022.2132798 |
| الوصول الحر: | https://doaj.org/article/69fd1c0e4ee14e64b06762577fb40081Test |
| رقم الانضمام: | edsdoj.69fd1c0e4ee14e64b06762577fb40081 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 21645515 2164554X |
|---|---|
| DOI: | 10.1080/21645515.2022.2132798 |